Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Earnings Call Insights: Biogen Inc. (BIIB) Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now ...

Biogen raised its full-year earnings forecast Thursday as cost-cutting and the rollout of new products, including the closely watched Alzheimer’s drug Leqembi, helped make up for declining sales ...

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Leqembi’s $40 million in Q2 sales beat analyst expectations, as it had a slow uptake – bringing in just $10 million last year following its launch. Earlier this year, Biogen said about 5,000 people ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Biogen shares the $26,500-a-year drug with its Japanese business partner Eisai, the lead developer of Leqembi. Eisai is expected to share more information about the medicine in an earnings call on ...